Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
Open Access
- 2 October 2011
- journal article
- Published by Wiley in Genes to Cells
- Vol. 16 (11), 1071-1080
- https://doi.org/10.1111/j.1365-2443.2011.01552.x
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Engineered therapeutic antibodies with improved effector functionsCancer Science, 2009
- Glycosylation as a strategy to improve antibody-based therapeuticsNature Reviews Drug Discovery, 2009
- Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc SialylationScience, 2006
- The Carbohydrate at FcγRIIIa Asn-162Published by Elsevier BV ,2006
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D-Biological Crystallography, 2004
- IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylationImmunological Reviews, 1998
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D-Biological Crystallography, 1994
- Human Antibody Effector FunctionAdvances in Immunology, 1992
- The interpretation of protein structures: Estimation of static accessibilityJournal of Molecular Biology, 1971
- Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei ThierenDeutsche Medizinische Wochenschrift (1946), 1890